- Laurus Labs is restructuring its CDMO operations by demerging Unit-1 (API manufacturing) from LSPL and merging the remaining business into Laurus Labs Ltd.
- The move is expected to streamline operations, optimise resource utilisation, and enhance financial flexibility, with no new shares issued for the amalgamation.
Laurus Labs is undertaking a strategic restructuring of its contract development and manufacturing (CDMO) operations. The company is demerging Unit-1, the API manufacturing portion of Laurus Synthesis Pvt Ltd (LSPL), and merging the remaining LSPL business into Laurus Labs Ltd. The process will dissolve LSPL without winding up under the Companies Act.
As part of the reorganisation, Sriam Labs, a wholly-owned subsidiary specialising in API and intermediary manufacturing, will issue 27 fully paid-up equity shares of Rs 10 each for every one share of Rs 10 held by LSPL. There will be no cash consideration for the merger, and the shareholding pattern of Laurus Labs will remain unchanged.
The company anticipates that the restructuring will bolster Laurus Labs’ growth prospects, operational capabilities, and financial position. The move is expected to simplify the group structure, optimise resource utilisation, and strengthen financial flexibility.
The transaction is exempt from related party transaction provisions under the Companies Act, 2013, and SEBI regulations. The scheme has been approved by the company’s board on 21 August 2025.
The appointed date for the merger is set for 1 April 2026, pending necessary approvals from the National Company Law Tribunal and other regulatory authorities.
